Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Wall Street Analysts Forecast Growth
Separately, BTIG Research lowered their price objective on shares of Freeline Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.75.
Freeline Therapeutics Stock Performance
NASDAQ:FRLN traded down $0.01 during trading on Friday, hitting $0.95. The stock had a trading volume of 26,879 shares, compared to its average volume of 127,639. The company has a market capitalization of $59.23 million, a PE ratio of -0.34 and a beta of 0.01. Freeline Therapeutics has a 12 month low of $0.65 and a 12 month high of $4.25. The company's 50-day moving average price is $0.87 and its two-hundred day moving average price is $0.95.
Freeline Therapeutics (NASDAQ:FRLN - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.05). As a group, equities analysts anticipate that Freeline Therapeutics will post -1.83 earnings per share for the current fiscal year.